Michal Rose, MD
ProfessorDownloadHi-Res Photo
Cards
Appointments
Medical Oncology
Primary
Additional Titles
Director, VA Comprehensive Cancer Center
Chief, Veterans Affairs
Contact Info
Appointments
Medical Oncology
Primary
Additional Titles
Director, VA Comprehensive Cancer Center
Chief, Veterans Affairs
Contact Info
Appointments
Medical Oncology
Primary
Additional Titles
Director, VA Comprehensive Cancer Center
Chief, Veterans Affairs
Contact Info
About
Titles
Professor
Director, VA Comprehensive Cancer Center; Chief, Veterans Affairs
Appointments
Medical Oncology
ProfessorPrimary
Other Departments & Organizations
Education & Training
- Resident
- Yale University School of Medicine, Internal Medicine (1999)
- Fellow
- Yale University School of Medicine, Hematology & Oncology (1996)
- Resident
- Hadassah Hospital Mount Scopus, Internal Medicine (1993)
- MD
- Hebrew University (1987)
Research
Overview
Medical Subject Headings (MeSH)
Health Services Research; Hematology; Medical Oncology; Veterans
Research at a Glance
Yale Co-Authors
Frequent collaborators of Michal Rose's published research.
Publications Timeline
A big-picture view of Michal Rose's research output by year.
Research Interests
Research topics Michal Rose is interested in exploring.
Ellice Wong, MD
Herta Chao, MD, PhD
Kathleen Akgün, MD, MS
Ling Han, MD, PhD, MS
Lori Bastian, MD, MPH
Jeffrey Kravetz, MD
25Publications
247Citations
Medical Oncology
Publications
2024
Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations
Jayakrishnan R, Kwiatkowski D, Rose M, Nassar A. Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations. The Oncologist 2024, 29: 833-841. PMID: 38907669, PMCID: PMC11449018, DOI: 10.1093/oncolo/oyae091.Peer-Reviewed Original ResearchAltmetricConceptsMutational signaturesNon-small cell lung cancerBase substitutionsNon-small lung cancerCell lung cancerLung cancerSingle base substitutionsDoublet base substitutionsResponse to personalized treatmentGenomics effortsMutational signature analysisGenesis of cancerLoss of mismatch repairResponse to therapyMutational processesDamaged DNAAPOBEC activityMismatch repairRepair mechanismsTumor evolutionEndogenous processesMutationsPersonalized treatmentCancerTobacco smokeOutcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation
Su D, Rehman S, Wang K, Deng Y, Rose M, Dosani T, Kunstman J. Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation. Journal Of Surgical Research 2024, 301: 10-17. PMID: 38905768, DOI: 10.1016/j.jss.2024.04.033.Peer-Reviewed Original ResearchAltmetricConceptsHematology consultationSingle-center retrospective studyClavien-Dindo classificationVA Connecticut Healthcare SystemAssess operative outcomesTime to resolutionPrimary outcome measureE-consultationOperative morbidityPostoperative transfusionHematologic complicationsSurgical outcomesNo significant differenceRetrospective studyProcedural dataOperative outcomesProcedural outcomesStudy cohortPatient characteristicsConsult volumeSecondary outcomesHematologic issuesAssociated with changesReferral patternsSurgerySystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights
Rose M, Kennedy E, Abou-Alfa G, Finn R, Gade T, Kelley R, Taddei T, Gordan J. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights. JCO Oncology Practice 2024, 20: 1035-1039. PMID: 38662970, DOI: 10.1200/op.24.00189.Peer-Reviewed Original ResearchCitationsAltmetricSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan J, Kennedy E, Abou-Alfa G, Beal E, Finn R, Gade T, Goff L, Gupta S, Guy J, Hoang H, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb A, Kelley R, Kortmansky J, Leaf A, Remak W, Sohal D, Taddei T, Wilson Woods A, Yarchoan M, Rose M. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal Of Clinical Oncology 2024, 42: 1830-1850. PMID: 38502889, DOI: 10.1200/jco.23.02745.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTyrosine kinase inhibitorsAdvanced hepatocellular carcinomaSecond-line therapyFirst-line treatmentRandomized controlled trialsHepatocellular carcinomaSystemic therapyFirst-lineChild-Pugh class A liver diseaseEastern Cooperative Oncology Group performance status 0Child-Pugh class A patientsSecond-line therapy optionsFirst-line settingPerformance status 0Third-line therapyFirst-line therapyClass A patientsEvidence-based guidelinesTolerated sorafenibStatus 0A patientsMechanism of actionTherapy optionsClinical decision-makingGuideline update
2023
Multiple Annual Low Dose CT Scans Needed to Detect Malignancy: Number Needed to Scan 蠅4
Bernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Akgun K, Cain H, Rose M. Multiple Annual Low Dose CT Scans Needed to Detect Malignancy: Number Needed to Scan 蠅4. 2023, a2732-a2732. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2732.Peer-Reviewed Original ResearchDisparities in Lung Cancer Screening in a Sample of Veterans
Bernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Rose M, Cain H, Akgun K. Disparities in Lung Cancer Screening in a Sample of Veterans. 2023, a2733-a2733. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2733.Peer-Reviewed Original ResearchTime to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening
Bernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Rose M, Akgun K, Cain H. Time to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening. 2023, a2734-a2734. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2734.Peer-Reviewed Original ResearchMyelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments
Rose M, Zeidan A. Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments. The Cancer Journal 2023, 29: 109-110. PMID: 37195765, DOI: 10.1097/ppo.0000000000000663.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAltmetricMeSH Keywords and Concepts
2022
A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut
Xiang J, Dosani T, Hauser R, Cosentino D, Merchant N, Rose M. A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut. Blood 2022, 140: 7864-7865. DOI: 10.1182/blood-2022-168044.Peer-Reviewed Original Research
2021
Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience.
Xiang J, Roy A, Summers C, Delvy M, O'Donovan J, Christensen J, Perry L, Connery D, Rose M, Chao H. Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience. Journal Of Clinical Oncology 2021, 39: 79-79. DOI: 10.1200/jco.2020.39.28_suppl.79.Peer-Reviewed Original ResearchCitationsConceptsLung cancer patientsCancer CenterClinical research recruitmentStudy enrollmentCancer patientsClinical trialsPotential eligibilityEligibility criteriaNew lung cancer patientsResearch enrollmentPotential study patientsCancer Center experienceTherapeutic clinical trialsNumber of patientsDiagnosis of cancerResearch recruitmentEligible patientsMalignancy workupPrimary oncologistStudy patientsChart reviewClinic visitsGenitourinary cancersPatient demographicsCenter experience
News
News
- March 28, 2023
Appointments & Promotions Committee Facilitates Faculty Success
- March 05, 2023
Dr. Michal Rose on Yale Cancer Answers
- May 01, 2018
Collaboration of Care to Battle a Rare Cancer
- June 07, 2016
Caring for our Veterans